Total Funding
90
71
Total FundingPost-IPO Equity raised
Growth Score
-4 pts
Heat Score
-19 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
144207
Captor Therapeutics is a bio-pharmaceutical firm focused on development of protein degradation drugs for cancer and autoimmune diseases.
- Sylvain Cottens: Co-Founder and SVP Chemistry
Tom Shepherd: Chief Executive Officer and President of the Management BoardPast Role: Kymab, Chief Business Officer
About the Company
Captor Therapeutics is a bio-pharmaceutical firm focused on development of protein degradation drugs for cancer and autoimmune diseases.
Targeted Protein Degradation (TPD) combats the therapeutic limits of small molecules with overcoming drug resistance and uncoupling their pharmacokinetics from pharmacodynamics. Breakthrough TPD technology allows
degradation of virtually any intracellular protein including the so-called "undruggable proteome".
